IN184589B
(zh)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
WO2001037804A2
(en)
*
|
1999-11-22 |
2001-05-31 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US20020041884A1
(en)
*
|
2000-03-07 |
2002-04-11 |
Evans Robert K. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
ATE285756T1
(de)
*
|
2001-06-28 |
2005-01-15 |
Microchips Inc |
Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
|
WO2003048665A1
(en)
|
2001-12-03 |
2003-06-12 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
US20040009213A1
(en)
*
|
2002-03-13 |
2004-01-15 |
Thomas Skold |
Water-based delivery systems
|
JP4436258B2
(ja)
*
|
2002-08-16 |
2010-03-24 |
マイクロチップス・インコーポレーテッド |
制御された放出デバイスおよび方法
|
AU2003278766A1
(en)
*
|
2002-09-04 |
2004-03-29 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
EP1545593A1
(en)
*
|
2002-09-27 |
2005-06-29 |
PowderJect Research Limited |
Nucleic acid coated particles
|
EP1551499A1
(en)
|
2002-10-04 |
2005-07-13 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
DK2526996T3
(da)
|
2002-12-20 |
2019-12-02 |
Xeris Pharmaceuticals Inc |
Formulering til intrakutan injektion
|
US8084424B2
(en)
*
|
2003-04-09 |
2011-12-27 |
University Of Utah Research Foundation |
Compositions and methods related to erythropoietin
|
ES2359243T3
(es)
*
|
2003-04-25 |
2011-05-19 |
Boston Scientific Scimed, Inc. |
Formulación de fármaco sólida y dispositivo para el almacenamiento y la administración controlada de la misma.
|
US7892205B2
(en)
*
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
AU2004285603A1
(en)
*
|
2003-11-03 |
2005-05-12 |
Microchips, Inc. |
Medical device for sensing glucose
|
AU2005327211A1
(en)
*
|
2004-06-01 |
2006-08-17 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
WO2006015299A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
ATE424928T1
(de)
*
|
2004-09-01 |
2009-03-15 |
Microchips Inc |
Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
|
BRPI0515061B8
(pt)
*
|
2004-09-10 |
2021-06-22 |
Becton Dickinson Co |
dispositivo de infusão e método para reduzir a formação de bolhas na reconstituição de uma fórmula
|
US7488316B2
(en)
|
2005-01-25 |
2009-02-10 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US9301919B2
(en)
*
|
2005-12-22 |
2016-04-05 |
Oakwood Laboratories, Llc |
Sublimable sustained release delivery system and method of making same
|
AU2007266475B2
(en)
|
2006-05-30 |
2009-12-03 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
DK2359808T3
(da)
|
2006-08-09 |
2013-08-05 |
Intarcia Therapeutics Inc |
Osmotiske leveringssystemer og stempelaggregater
|
SI2134353T1
(sl)
*
|
2007-03-30 |
2017-03-31 |
Xisle Pharma Ventures Trust |
Dvofazni sestavek lipidnih veziklov in postopek za zdravljenje cervikalne displazije z intravaginalnim dajanjem
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
HUE043228T2
(hu)
|
2007-06-22 |
2019-08-28 |
Univ Texas |
Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
|
CA2726861C
(en)
*
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
WO2010056657A2
(en)
|
2008-11-16 |
2010-05-20 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
WO2010059253A2
(en)
*
|
2008-11-24 |
2010-05-27 |
Massachusets Institute Of Technology |
Methods and compositions for localized agent delivery
|
ES2650667T3
(es)
|
2009-09-28 |
2018-01-19 |
Intarcia Therapeutics, Inc |
Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
ES2659079T3
(es)
*
|
2010-03-09 |
2018-03-13 |
Janssen Biotech, Inc. |
Formulaciones no acuosas en suspensión de viscosidad reducida a concentración elevada
|
CN102869345B
(zh)
|
2010-03-17 |
2015-02-11 |
诺瓦利克有限责任公司 |
用于治疗眼内压增高的药物组合物
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CA2829400C
(en)
|
2011-03-10 |
2022-02-15 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of peptide drugs
|
EP2714008B1
(en)
|
2011-05-25 |
2016-12-14 |
Novaliq GmbH |
Pharmaceutical composition for administration to nails
|
JP6039145B2
(ja)
|
2011-05-25 |
2016-12-07 |
ノバリック ゲーエムベーハー |
半フッ化アルカンを基礎にした局所薬学的組成物
|
WO2013067022A1
(en)
|
2011-10-31 |
2013-05-10 |
Xeris Pharmaceuticals, Inc. |
Formulations for the treatment of diabetes
|
KR101989648B1
(ko)
|
2012-01-23 |
2019-06-14 |
노바리크 게엠베하 |
부분불소화 알칸에 기초한 안정화된 단백질 조성물
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
AU2013314370B2
(en)
|
2012-09-12 |
2017-11-30 |
Novaliq Gmbh |
Compositions comprising mixtures of semifluorinated alkanes
|
DK3181119T3
(da)
|
2012-09-12 |
2019-09-16 |
Novaliq Gmbh |
Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
EP4137127A1
(en)
|
2013-01-11 |
2023-02-22 |
Corsair Pharma, Inc. |
Prodrugs of treprostinil
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
TWI745671B
(zh)
*
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
PT3024484T
(pt)
|
2013-07-23 |
2018-10-24 |
Novaliq Gmbh |
Composições de anticorpo estabilizadas
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
WO2015038777A1
(en)
|
2013-09-11 |
2015-03-19 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing water soluble organic dyes
|
WO2015048498A2
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
KR102385372B1
(ko)
|
2014-03-24 |
2022-04-11 |
바이오버라티브 테라퓨틱스 인크. |
동결건조된 ix 인자 제형
|
JP6561109B2
(ja)
|
2014-07-16 |
2019-08-14 |
コルセア ファーマ インコーポレイテッド |
トレプロスチニル誘導体化合物およびその使用方法
|
US11129940B2
(en)
|
2014-08-06 |
2021-09-28 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
MX2017004306A
(es)
|
2014-10-01 |
2017-12-20 |
Eagle Biologics Inc |
Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
|
MA44390A
(fr)
|
2015-06-03 |
2019-01-23 |
Intarcia Therapeutics Inc |
Systèmes de mise en place et de retrait d'implant
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
AU2016305087B2
(en)
|
2015-08-12 |
2022-01-20 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
JP6602964B2
(ja)
|
2015-09-30 |
2019-11-06 |
ノバリック ゲーエムベーハー |
半フッ素化化合物およびその組成物
|
CN113662928A
(zh)
|
2015-09-30 |
2021-11-19 |
诺瓦利克有限责任公司 |
用于眼部给药的半氟化化合物
|
WO2017200943A1
(en)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
WO2017218533A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
ES2763121T3
(es)
|
2016-06-23 |
2020-05-27 |
Novaliq Gmbh |
Método de administración tópica
|
MX2019003363A
(es)
|
2016-09-22 |
2019-10-02 |
Novaliq Gmbh |
Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
|
AU2017329983B2
(en)
|
2016-09-23 |
2022-05-05 |
Novaliq Gmbh |
Ophthalmic compositions comprising ciclosporin
|
US10835580B2
(en)
|
2017-01-03 |
2020-11-17 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
BR112019021917A8
(pt)
|
2017-04-21 |
2023-03-21 |
Novaliq Gmbh |
Composições de iodo
|
CN110650734A
(zh)
|
2017-05-12 |
2020-01-03 |
诺瓦利克有限责任公司 |
治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
CN117085022A
(zh)
|
2017-06-02 |
2023-11-21 |
Xeris药物公司 |
抗沉淀的小分子药物制剂
|
EP3678701A4
(en)
|
2017-09-05 |
2021-12-01 |
Torque Therapeutics, Inc. |
THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
|
CN111372566A
(zh)
|
2017-09-27 |
2020-07-03 |
诺瓦利克有限责任公司 |
用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
|
WO2019068763A1
(en)
|
2017-10-04 |
2019-04-11 |
Novaliq Gmbh |
OPHTHALMIC COMPOSITIONS COMPRISING F6H8
|
US11576893B2
(en)
|
2018-03-02 |
2023-02-14 |
Novaliq Gmbh |
Pharmaceutical compositions comprising nebivolol
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
WO2020074697A1
(en)
|
2018-10-12 |
2020-04-16 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
KR20210125032A
(ko)
|
2019-02-05 |
2021-10-15 |
린디 바이오사이언시스, 아이엔씨. |
세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
|
WO2021109979A1
(en)
*
|
2019-12-06 |
2021-06-10 |
Guangzhou Bioseal Biotech Co., Ltd. |
Flowable fibrinogen thrombin paste
|
US20230101362A1
(en)
*
|
2021-09-16 |
2023-03-30 |
Team Medical Llc |
Rna stabilization
|